The impaired response of circulating asprosin concentrations to glucose levels fluctuation may be one of the causes of type 2 diabetes – a narrative review
DOI:
https://doi.org/10.12775/JEHS.2020.10.09.102Keywords
asprosin, adipokine, diabetes mellitus, obesityAbstract
It has been recently discovered that asprosin, an adopakine that is secreted by white adipose tissue, affects the release of glucose into the blood. When blood glucose levels rise, the production of asprosin is immediately suppressed. In healthy people, circulating asprosin shows daily fluctuations, and its concentration drops significantly with the beginning of eating. In patients with type 2 diabetes it was invastigated that both fasting and postprandial asprosin concentrations were significantly higher. Therefore, it is probable that elevated blood levels of asprosin and its impaired response to glucose levels fluctuation may be one of the causes of type 2 diabetes. It is considered, that administration of antibodies that block the action of asprosin may help diabetics reduce glucose levels. In addition, it can also contribute to the effective fight against obesity.
References
Yi-Ching W, Sung-Sheng T, Rong-Kuo L, Chun-Che Ch, Long-Sun R, Ming-Feng L, Hong-Shiu Ch, Chiung-Mei Ch, Jawl-Shan H, and Hung-Chou K, Diabetic Distal Symmetrical Polyneuropathy: Correlation of Clinical, Laboratory, and Electrophysiologic Studies in Patients with Type 2 Diabetes Mellitus, J Diabetes Res. 2020(8):1-11, originally published online 2020 Jul 3
Xinyue Z, Hui J, Xiaojing M, and Hongyan W, Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitu, J Diabetes Investig. 2020 Mar; 11(2): 349–355. Published online 2019 Oct 3
Yuren W, Hua Q, Xin X, Yuyang Q, Yong L, Yingchun C, Yi Z, and Hongting Z, Plasma Asprosin Concentrations Are Increased in Individuals with Glucose Dysregulation and Correlated with Insulin Resistance and First-Phase Insulin Secretion, Mediators Inflamm. 2018:1-7. Published online 2018 Mar 20
Lei Z, Chao C, Nan Z, Yuming F, Xingbo C, Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride, Clinica Chimica Acta 2017(489):183-188
Azamar-Llamas D, Hernández-Molina G, Ramos-Ávalos B, Furuzawa-Carballeda J, Adipokine Contribution to the Pathogenesis of Osteoarthritis, Mediators Inflamm. 2017(5468023):26, Published online 09 Apr 2017
Helfer G, Qing-Feng W, Chemerin: a multifaceted adipokine involved in metabolic disorders, , J Endocrinol 2018 Aug;238(2):R79-R94
Shakiba N, Mohsen N, Mehdi Z, Moslem L N, Ali G, Mohammad R B, Hafez H, and Mohammad M, Serum concentration of asprosin in new-onset type 2 diabetes, Diabetol Metab Syndr. (2020) 12:65. Published online 2020 Jul 23
Muthu L M, Dieter P R, Fibrillin-1 and fibrillin-1-derived asprosin in adipose tissue function and metabolic disorders, J Cell Commun Signal 2020 Jun;14(2):159-173
Hongyu Z, Wenqi H, Guang Z, Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease, International Urology and Nephrology 2020, 52:1517–1522
Hoffmann J G, Xie W, Atul R C, Energy Regulation Mechanism and Therapeutic Potential of Asprosin, Diabetes 2020 Apr;69(4):559-566
Xing L, Mingyu L, Rufei S, Linlin Z, Hua H, Jun W, Xiuli W, Hua Q, Shaodong G, Min L and Hongting Z, Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases, Mediators Inflamm. 2018(1):1-12. Published online 2018 Nov 6
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 484
Number of citations: 0